Navigation Links
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
Date:3/30/2009

RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose levels.

For a 12-week period, 34 participants ingested four grams of "Sun Chlorella A" tablets each morning and evening. Seventeen subjects were healthy; the other 17 were at high risk for developing lifestyle-related illnesses.

Both groups had a decrease in body fat percentage and total serum cholesterol. However, the high-risk group also experienced lowered blood glucose, possibly due to improved insulin sensitivity induced by adding Chlorella to the daily diet.

Heart disease and stroke are the number one and three causes of death for both men and women in the U.S. Risk factors include elevated serum cholesterol, high blood pressure, a sedentary lifestyle, unhealthy diet, smoking, obesity, and hyperglycemia.

According to Mark Drucker, M.D., "Heart health is important to everyone. Remember, our hearts must be nourished to stay healthy. With protein, minerals, vitamins and fiber, Sun Chlorella is what I take, and what I recommend to all my patients."

Chlorella is a single-cell, fresh water green alga. Past research has shown that Chlorella is effective for immune activation, growth promotion, and detoxification of heavy metals and pesticides. However, unlike this recent study, most of the prior research used laboratory animals.

Dr. Randall E. Merchant earned his Doctoral and Master of Sciences degrees from the University of North Dakota. Dr. Merchant is a Professor of Anatomy and Neurosurgery at Virginia Commonwealth University, and has conducted several clinical investigations on the role of nutrition on overcoming the effects of certain chronic illnesses.

References

Toru Mizoguchi, Isao Takehara, Tohru Masuzawa, Toshiro Saito, and Yo Naoki, "Nutrigenomic Studies of Effects of Chlorella on Subjects with High-Risk Factors for Lifestyle-Related Diseases", JOURNAL OF MEDICINAL FOOD, J Med Food 11 (3) 2008, 395-404

Janet Poveromo, Aiming for the Heart to Target Cardiovascular Health Specifically Ingredient Companies are Broadening their Scope of What's Beneficial, niemagazine.com, October 2008


'/>"/>
SOURCE Randall E. Merchant, Ph.D.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):